- Home
- AKA vs MGNX Comparison
AKA vs MGNX Comparison
Compare AKA & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKA | MGNX |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.4M | 115.8M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | AKA | MGNX |
|---|---|---|
| Price | $10.34 | $3.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $24.33 | $4.60 |
| AVG Volume (30 Days) | 2.6K | ★ 864.3K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $600,208,000.00 | $149,500,000.00 |
| Revenue This Year | $6.14 | N/A |
| Revenue Next Year | $4.89 | $16.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.44 | N/A |
| 52 Week Low | $7.00 | $1.19 |
| 52 Week High | $16.38 | $3.88 |
Technical Indicators
Market Signals| Indicator | AKA | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 52.87 | 59.95 |
| Support Level | $8.94 | $1.48 |
| Resistance Level | $10.53 | N/A |
| Average True Range (ATR) | 0.54 | 0.24 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 46.31 | 56.96 |
Price Performance
Historical ComparisonAbout AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is a portfolio of fashion brands, including Princess Polly, Culture Kings, Petal & Pup, and mnml. Through these brands, the company reaches next-generation consumers who seek fashion inspiration on social media and mainly shop online. The portfolio consists of two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company generates the majority of its revenue from the United States.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.